IPSC Century Therapeutics Inc.

Biotech Analyst Ratings

Latest News

1. 16 May 2022 Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

   - Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence in the second half of 2022 following IND submission in mid 2022-
   

   - Ended first quarter 2022 with cash, cash equivalents, and investments of $466.4M; Cash runway into 2025 -

   PHILADELPHIA, May 16, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc., (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the first quarter ended March 31, 2022.

   "We are off to a strong start in 2022, which we expect will be a transformational year for Century as we transition into a clinical-stage organization," said Lalo Flores…

   View Full Article
2. 03 May 2022 Century Therapeutics to Present at Upcoming Investor Conferences

   PHILADELPHIA, May 03, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will participate in the following investor conferences in May:
   

   • The Bank of America Securities 2022 Healthcare Conference. The fireside chat will take place at 8:40 AM PT/ 11:40 AM ET on Tuesday, May 10, 2022.
     
     
   • The H.C. Wainwright Global Investment Conference. The presentation will be available on-demand beginning at 7:00 AM ET on Tuesday, May 24, 2022.
     

   A replay of the events will be available on the "Events & Presentations" page in the "Investors" section of the Company's website at…

   View Full Article
3. 02 May 2022 Century Therapeutics to Present at the ASGCT 25th Annual Meeting

   PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that preclinical data on MAD7, a novel CRISPR nuclease used to enable the genetic engineering of iPSC-derived NK and T cell product candidates, will be presented in a poster at the American Society of Gene and Cell Therapy (ASGCT) 25^th Annual Meeting, on May 16-19, 2022 in Washington, D.C.

   Details of the poster presentations are as follows:

   Abstract Number: 952
   Title: Enabling the Engineering of iPSC Based Cell Therapies Using MAD7, a Novel CRISPR Nuclease
   Poster Board Number: W-78
   Session Title: Gene Targeting and Gene…

   View Full Article
4. 18 April 2022 Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit

   PHILADELPHIA, April 18, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will present at the virtual Chardan Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 25, 2022, at 9:30 AM ET.
   

   A live webcast of the event will be available on the "Events & Presentations" page in the "Investors" section of the Company's website at https://investors.centurytx.com/events-and-presentations. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.

   About Century Therapeutics

   Century Therapeutics…

   View Full Article
5. 06 April 2022 Century Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

   PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at the 21^st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 10:15 AM ET and participate in a panel titled "Company Perspectives: Companies Discussing Key Features and Differentiators in the NK Cellular Therapeutics Space" on April 14, 2022, at 11:00 AM ET.
   

   A live webcast of the podium presentation will be available on the "Events & Presentations" page in the "Investors" section of the Company's website at https://investors.centurytx.com/events-and-presentations…

   View Full Article